Protocol for PD SENSORS: Parkinson’s Disease Symptom Evaluation in a Naturalistic Setting producing Outcome measuRes using SPHERE technology. An observational feasibility study of multi-modal multi-sensor technology to measure symptoms and activities of daily living in Parkinson’s disease

Introduction The impact of disease-modifying agents on disease progression in Parkinson’s disease is largely assessed in clinical trials using clinical rating scales. These scales have drawbacks in terms of their ability to capture the fluctuating nature of symptoms while living in a naturalistic environment. The SPHERE (Sensor Platform for HEalthcare in a Residential Environment) project has designed a multi-sensor platform with multimodal devices designed to allow continuous, relatively inexpensive, unobtrusive sensing of motor, non-motor and activities of daily living metrics in a home or a home-like environment. The aim of this study is to evaluate how the SPHERE technology can measure aspects of Parkinson’s disease. Methods and analysis This is a small-scale feasibility and acceptability study during which 12 pairs of participants (comprising a person with Parkinson’s and a healthy control participant) will stay and live freely for 5 days in a home-like environment embedded with SPHERE technology including environmental, appliance monitoring, wrist-worn accelerometry and camera sensors. These data will be collected alongside clinical rating scales, participant diary entries and expert clinician annotations of colour video images. Machine learning will be used to look for a signal to discriminate between Parkinson’s disease and control, and between Parkinson’s disease symptoms ‘on’ and ‘off’ medications. Additional outcome measures including bradykinesia, activity level, sleep parameters and some activities of daily living will be explored. Acceptability of the technology will be evaluated qualitatively using semi-structured interviews. Ethics and dissemination Ethical approval has been given to commence this study; the results will be disseminated as widely as appropriate.

[1]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[2]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[3]  M. Morris,et al.  Reliability of measurements obtained with the Timed "Up & Go" test in people with Parkinson disease. , 2001, Physical therapy.

[4]  A. Stiggelbout,et al.  Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments , 2002, Journal of neurology, neurosurgery, and psychiatry.

[5]  Academisch Proefschrift,et al.  UvA-DARE ( Digital Academic Repository ) Clinimetrics , clinical profile and prognosis in early Parkinson ’ s disease , 2009 .

[6]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[7]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.

[8]  Geert Mayer,et al.  The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.

[9]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Jankovic.  Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  M Zappia,et al.  International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease , 2009, Neurology.

[12]  G. Earhart,et al.  Measuring participation in individuals with Parkinson disease: relationships with disease severity, quality of life, and mobility , 2011, Disability and rehabilitation.

[13]  Kallol Ray Chaudhuri,et al.  Parkinson's disease sleep scale—validation of the revised version PDSS‐2 , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  G M Earhart,et al.  Which measures of physical function and motor impairment best predict quality of life in Parkinson's disease? , 2011, Parkinsonism & related disorders.

[15]  P. Kempster,et al.  Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. , 2012, Journal of Parkinson's disease.

[16]  Larry D. Rosen,et al.  The Media and Technology Usage and Attitudes Scale: An empirical investigation , 2013, Comput. Hum. Behav..

[17]  W. Poewe,et al.  Trial designs used to study neuroprotective therapy in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[18]  Verónica Robles-García,et al.  Spatiotemporal Gait Patterns During Overt and Covert Evaluation in Patients With Parkinson´s Disease and Healthy Subjects: Is There a Hawthorne Effect? , 2015, Journal of applied biomechanics.

[19]  Majid Mirmehdi,et al.  Real-time RGB-D Tracking with Depth Scaling Kernelised Correlation Filters and Occlusion Handling , 2015, BMVC.

[20]  Niall Twomey,et al.  Bridging e-Health and the Internet of Things: The SPHERE Project , 2015, IEEE Intelligent Systems.

[21]  Majid Mirmehdi,et al.  A comparative home activity monitoring study using visual and inertial sensors , 2015, 2015 17th International Conference on E-health Networking, Application & Services (HealthCom).

[22]  David Coyle,et al.  Empirically derived user attributes for the design of home healthcare technologies , 2015, Personal and Ubiquitous Computing.

[23]  A. Espay,et al.  A Viewpoint on Wearable Technology-Enabled Measurement of Wellbeing and Health-Related Quality of Life in Parkinson’s Disease , 2016, Journal of Parkinson's disease.

[24]  David Coyle,et al.  Shared Language and the Design of Home Healthcare Technology , 2016, CHI.

[25]  Ahmed Al-Jawad,et al.  A systematic review of the characteristics and validity of monitoring technologies to assess Parkinson’s disease , 2016, Journal of NeuroEngineering and Rehabilitation.

[26]  C. Mazzà,et al.  Free‐living monitoring of Parkinson's disease: Lessons from the field , 2016, Movement disorders : official journal of the Movement Disorder Society.

[27]  C. Ritchie,et al.  A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease , 2016, BMC Neurology.

[28]  D. Heldman,et al.  Prospective study on cost-effectiveness of home-based motor assessment in Parkinson’s disease , 2017, Journal of telemedicine and telecare.

[29]  Niall Twomey,et al.  SPHERE: A sensor platform for healthcare in a residential environment , 2017 .

[30]  Michael R Whitehouse,et al.  Using home sensing technology to assess outcome and recovery after hip and knee replacement in the UK: the HEmiSPHERE study protocol , 2018, BMJ Open.

[31]  Arantza Illarramendi,et al.  Using Kinect to classify Parkinson’s disease stages related to severity of gait impairment , 2018, BMC Bioinformatics.

[32]  Paolo Bonato,et al.  A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies , 2019, Movement disorders : official journal of the Movement Disorder Society.

[33]  B. Bloem,et al.  Home‐based monitoring of falls using wearable sensors in Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[34]  Milica Đurić-Jovičić,et al.  Artificial intelligence for assisting diagnostics and assessment of Parkinson’s disease—A review , 2019, Clinical Neurology and Neurosurgery.

[35]  L. Rochester,et al.  Systematic Review Looking at the Use of Technology to Measure Free-Living Symptom and Activity Outcomes in Parkinson’s Disease in the Home or a Home-like Environment , 2020, Journal of Parkinson's disease.

[36]  L. Lopiano,et al.  Implementation of Mobile Health Technologies in Clinical Trials of Movement Disorders: Underutilized Potential , 2020, Neurotherapeutics.